SAN JOSE, Calif., Dec. 18 /PRNewswire/ -- Patent 7,309,486 issued on 12/18/07 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses a better way of using Genentech's drug Herceptin(R) against breast cancer. The patent discloses that today's practice of concurrent administration of Herceptin(R) with conventional phase specific chemotherapy results in antagonistic action between the two classes of drugs. In later stage cancers, these protocols only increase median survival by several months.
Patent 7,309,486 discloses novel protocols that allow the two classes of chemotherapeutics to function synergistically. The protocols are designed to provide a way of holding the cancer in check indefinitely.
All proliferating cells progress through 4 distinct phases termed G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's Camptosar(R) or Eli Lilly's Gemzar(R), are capable of killing virtually all cells that are in the S-Phase, however, in the best case, only around one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "The patented protocols boost the number of cells in the S-Phase by exploiting the cancer's unique mutation profile to establish a "road block" to aggregate a large number of cancer cells at a point prior to the S-Phase, the road block is then removed to allow the wave of cancer cells to enter the S-Phase during the administration time of the S-Phase cytotoxic chemotherapy, and then the road block is reestablished to start aggregating surviving cancer cells for the next administration of S-Phase cytotoxic chemotherapy."
The abstract contained in the patent has been incorrectly truncated and a correct synopsis of the patent is available at http://www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.
|SOURCE NexGen Biomedical, Inc.|
Copyright©2007 PR Newswire.
All rights reserved